Table 2.

Clinical and biologic variables associated with overall mortality and hepatocellular carcinoma occurrence in patients without hepatocellular carcinoma at baseline based on Cox univariable and multivariable models

Univariate analysisMultivariate analysis
VariablesHR (95% CI)PHR (95% CI)P
Overall survival
Gender (male)1.02 (0.36–2.88)0.97
Age/10 (years)1.11 (0.83–1.49)0.49
Child-Pugh
 A1
 B5.36 (2.30–12.48)0.00013.43 (1.26–9.37)0.016
 C6.74 (2.73–16.63)<0.00014.13 (1.42–12.04)0.009
Creatinine>801.08 (0.57–2.07)0.81
AST (>2ULN)0.51 (0.23–1.12)0.092
ALT (>2ULN)0.43 (0.10–1.82)0.25
ALP (>2ULN)0.68 (0.26–1.78)0.43
GGT (>2ULN)1.47 (0.60–3.60)0.39
Alpha-fetoprotein/101.00 (0.93–1.07)0.96
Platelet/1000.86 (0.51–1.46)0.58
Diabetes0.76 (0.27–2.14)0.60
Serum endocan >5 ng/mL5.75 (2.70–12.28)<0.00012.84 (1.18–6.84)0.02
Serum syndecan >501.18 (0.62–2.26)0.62
Serum glypican-3 >2.51.53 (0.80–2.93)0.20
Serum VEGF >2400.72 (0.36–1.43)0.34
Hepatocellular carcinoma occurence
Gender (male)1.91 (0.25–14.47)0.53
Age/10 (y)2.30 (1.42–3.71)0.00072.47 (1.43–4.26)0.0012
Child-Pugh
 A1
 B2.51 (0.93–6.76)0.068
 C0.55 (0.07–4.39)0.57
Creatinine >801.34 (0.51–3.49)0.55
AST (>2 ULN)0.77 (0.27–2.24)0.63
ALT (>2 ULN)1.08 (0.24–4.82)0.92
PAL (>2 ULN)1.25 (0.39–3.99)0.70
GGT (>2 ULN)2.12 (0.48–9.48)0.32
AFP/101.02 (0.97–1.07)0.39
Platelet/1002.00 (1.07–3.72)0.0292.32 (1.18–4.55)0.015
Diabetes1.42 (0.40–4.99)0.59
Serum endocan >5 ng/mL1.73 (0.66–4.49)0.26
Serum syndecan-1 >500.88 (0.33–2.32)0.79
Serum glypican-3 >2.50.50 (0.18–1.43)0.20
Serum VEGF >2401.09 (0.41–2.89)0.86

NOTE: In bold, variables with P value < 0.05 in univariate analysis.

Abbreviations: ALT: alanine aminotransferase; ALP: alkaline phosphatase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; ULN, upper limit of normal.